Standard BioTools Inc.

LAB Healthcare Medical Devices

In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.63 0.03 −4.55%
Market cap
$258.5M
P/E
2.9×
Fwd P/E
−11.5×
Dividend yield
—
F-score
4/9
Altman Z
−0.82
Beneish M
−2.93
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
17.61% 15.40% (16.72%) (28.85%)

+8 more TTM periods

Piotroski F-Score
5 5 4 4
ROA
14.34% 12.83% (12.69%) (21.00%)
ROIC
(93.89%) (56.34%) (29.07%) (29.24%)
Return on Tangible Assets
17.86% 15.76% (20.51%) (33.29%)
Average Days of Receivables
67.94 176.19 57.45 79.14
Free Cash Flow per Share
(0.21) (0.24) (0.22) (0.26)
Free Cash Flow
(82.58) (94.48) (82.65) (98.42)
Other line items

Show all line items

Columns are period end dates